Page last updated: 2024-09-03

gefitinib and Papulosquamous Disorders

gefitinib has been researched along with Papulosquamous Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ashida, A; Koizumi, T; Ogawa, E; Okuyama, R; Uhara, H	1

Other Studies

1 other study(ies) available for gefitinib and Papulosquamous Disorders

Article	Year
Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash. Journal of dermatological science, 2016, Volume: 82, Issue:1 Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; NF-kappa B; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Sebaceous Glands; Signal Transduction; Skin Diseases, Papulosquamous; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation	2016

Article

Year

Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash.

Journal of dermatological science, 2016, Volume: 82, Issue:1

Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; NF-kappa B; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Sebaceous Glands; Signal Transduction; Skin Diseases, Papulosquamous; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation

2016